Topic

Deals

Acquisitions, licensing agreements and partnerships across the sector.

TrackerCross-border deals

Western drugmakers have signed 37 licensing deals for China-originated medicines this year, already more than in all of 2025.

Updated Sept. 29, 2026Deals

Sept. 27, 2026Deals

Deep Dive

Buyers have announced 19 acquisitions worth $1 billion or more this year, with rare disease companies the most frequent targets.

Updated Sept. 22, 2026Deals

Obesity drugs

Sept. 17, 2026Deals

The day in drug development, by 7 a.m.

One email each weekday with the stories our editors would send a colleague. Free, and you can leave whenever you like.